KR20130139254A - 피부 침투 및 세포 진입（ｓｐａｃｅ） 펩타이드 및 그의 사용방법 - Google Patents

피부 침투 및 세포 진입（ｓｐａｃｅ） 펩타이드 및 그의 사용방법 Download PDF

Info

Publication number
KR20130139254A
KR20130139254A KR1020137008413A KR20137008413A KR20130139254A KR 20130139254 A KR20130139254 A KR 20130139254A KR 1020137008413 A KR1020137008413 A KR 1020137008413A KR 20137008413 A KR20137008413 A KR 20137008413A KR 20130139254 A KR20130139254 A KR 20130139254A
Authority
KR
South Korea
Prior art keywords
seq
composition
peptide
sirna
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137008413A
Other languages
English (en)
Korean (ko)
Inventor
트레이시 수
사미르 엠 미트라고트리
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20130139254A publication Critical patent/KR20130139254A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020137008413A 2010-11-09 2011-10-05 피부 침투 및 세포 진입（ｓｐａｃｅ） 펩타이드 및 그의 사용방법 Withdrawn KR20130139254A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41188410P 2010-11-09 2010-11-09
US61/411,884 2010-11-09
US201161527574P 2011-08-25 2011-08-25
US61/527,574 2011-08-25
US201161528036P 2011-08-26 2011-08-26
US61/528,036 2011-08-26
PCT/US2011/054967 WO2012064429A2 (en) 2010-11-09 2011-10-05 Skin permeating and cell entering (space) peptides and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20130139254A true KR20130139254A (ko) 2013-12-20

Family

ID=46051476

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137008413A Withdrawn KR20130139254A (ko) 2010-11-09 2011-10-05 피부 침투 및 세포 진입（ｓｐａｃｅ） 펩타이드 및 그의 사용방법

Country Status (8)

Country Link
US (4) US8518871B2 (https=)
EP (1) EP2638162B1 (https=)
JP (1) JP2014500867A (https=)
KR (1) KR20130139254A (https=)
CN (1) CN103201386A (https=)
AU (1) AU2011326732B2 (https=)
CA (1) CA2811113A1 (https=)
WO (1) WO2012064429A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017082690A1 (ko) * 2015-11-12 2017-05-18 주식회사 펩트론 미백, 피부 탄력, 주름 개선 및 상처치유 활성을 갖는 다기능성 피부투과 펩타이드
WO2021157809A1 (ko) * 2020-02-06 2021-08-12 인천대학교 산학협력단 신규한 핵산 분자 전달용 조성물 및 그 용도

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8834423B2 (en) 2009-10-23 2014-09-16 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
KR20130139254A (ko) 2010-11-09 2013-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 피부 침투 및 세포 진입（ｓｐａｃｅ） 펩타이드 및 그의 사용방법
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
WO2013112488A2 (en) * 2012-01-23 2013-08-01 Kythera Biopharmaceuticals, Inc. Dermal filling compositions and methods
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP4112112A1 (en) 2012-05-01 2023-01-04 University of Pittsburgh - Of the Commonwealth System of Higher Education Tip-loaded microneedle arrays for transdermal insertion
US20150080320A1 (en) * 2012-05-16 2015-03-19 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
KR101329411B1 (ko) 2012-05-31 2013-11-14 주식회사 엘지생활건강 피부투과성 펩타이드
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
CN103897043A (zh) * 2012-12-28 2014-07-02 天津药物研究院 一种穿膜多肽连接拉帕替尼的制备及应用
WO2014123543A2 (en) * 2013-02-11 2014-08-14 Convoy Therapeutics Skin permeating and cell entering (space) peptides and methods of use therefor
US20140227174A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use therefor
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6063094B2 (ja) * 2013-08-12 2017-01-18 スリーエム イノベイティブ プロパティズ カンパニー 経皮送達を促進するためのペプチド
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
KR101602690B1 (ko) * 2013-11-14 2016-03-11 주식회사 엘지생활건강 염기성 섬유모세포성장인자 융합단백질을 포함하는 피부개선용 화장료 조성물
US9321821B2 (en) 2013-11-14 2016-04-26 Lg Household & Health Care Ltd. Cosmetic composition for improving skin conditions comprising fusion protein
US20170258930A1 (en) * 2014-08-27 2017-09-14 The Regents Of The University Of California Skin penetrating peptides (spps) and methods of use therefor
US11202820B2 (en) 2014-09-25 2021-12-21 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
WO2016071814A1 (en) 2014-11-04 2016-05-12 Università Degli Studi Di Milano A promoter for cutaneous absorption of active ingredients having peptidic structure
WO2016149673A1 (en) 2015-03-18 2016-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bioactive components conjugated to substrates of microneedle arrays
KR101841241B1 (ko) * 2015-09-10 2018-03-22 한양대학교 산학협력단 피부 질환에 대한 예방 또는 치료효과를 갖는 펩티드 융합체 및 이를 유효성분으로 하는 약학 조성물
WO2017043920A1 (ko) * 2015-09-10 2017-03-16 한양대학교 산학협력단 피부 투과성 펩티드 및 그 이용방법
WO2017048812A1 (en) * 2015-09-15 2017-03-23 The Regents Of The University Of California Skin-penetrating peptides and compositions and methods of use thereof
WO2017066768A1 (en) 2015-10-16 2017-04-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mullti-component biio-active drug delivery and controlled release to the skin by microneedle array devices
MX2018005146A (es) 2015-10-30 2018-08-23 Bonac Corp Composicion que contiene de manera estable molecula de acido nucleico de un solo filamento que suprime la expresion de gen tgf-b1.
US11744889B2 (en) 2016-01-05 2023-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Skin microenvironment targeted delivery for promoting immune and other responses
CN105504066A (zh) * 2016-01-16 2016-04-20 广州市科玮生物技术有限公司 一种融合蛋白在化妆品中的应用
US20190021988A1 (en) * 2016-01-23 2019-01-24 Bruce J. Sand Enhanced transdermal delivery of active agents
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
MX390709B (es) * 2017-04-17 2025-03-21 Ampersand Biopharmaceuticals Llc Administración parenteral no sistémica de agentes amortiguadores para inhibir la metástasis de tumores sólidos, hiperpigmentación y gota.
KR102083978B1 (ko) * 2017-12-18 2020-03-03 주식회사 엘지생활건강 혈소판유래 성장인자 a서브유닛의 융합 단백질을 포함하는 피부개선용 화장료 조성물
KR102083976B1 (ko) * 2017-12-18 2020-03-03 주식회사 엘지생활건강 혈관내피세포 성장인자의 융합 단백질을 포함하는 피부개선용 화장료 조성물
WO2019012149A1 (en) 2017-07-13 2019-01-17 Forrest Michael David THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
US10905738B2 (en) 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
BR112021020951A2 (pt) 2019-04-19 2021-12-14 Fount Bio Inc Dispensação e retenção de agentes ativos dentro da pele
CN113874065A (zh) 2019-05-16 2021-12-31 联邦高等教育系统匹兹堡大学 用于皮肤和非皮肤药物递送的具有底切特征的微针阵列
WO2021113410A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
CN113943778A (zh) * 2020-07-17 2022-01-18 通用电气医疗集团股份有限公司 用于核酸检测的分子探针及其制备方法和用途
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
CN114315960B (zh) * 2021-12-31 2022-10-14 深圳市维琪医药研发有限公司 一种经修饰的肽及其美容组合物或药用组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624011A5 (https=) 1977-08-05 1981-07-15 Battelle Memorial Institute
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US6083539A (en) 1994-12-16 2000-07-04 Sakuma Ebisu Kabushiki Kaisha Buckwheat starch syrup, method for preparing the same, and foods containing the same
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US20090070897A1 (en) 2006-01-12 2009-03-12 Goldman Barry S Genes and uses for plant improvement
JP4596391B2 (ja) 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
JP2007143454A (ja) * 2005-11-25 2007-06-14 Toray Ind Inc 細胞膜通過性ペプチド
CA2633063A1 (en) * 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids intocells
GB0606415D0 (en) 2006-03-31 2006-05-10 Univ Southampton Topical drug delivery
EP2099496A2 (en) 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
JP2008200011A (ja) * 2007-02-22 2008-09-04 Toray Ind Inc 細胞内移行性ペプチド、それを含有する医薬組成物及びその使用方法
AU2008295509A1 (en) 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
WO2010039088A1 (en) * 2008-09-16 2010-04-08 Kariem Ahmed Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds
US8389481B2 (en) * 2008-11-12 2013-03-05 University Of Medicine And Dentistry Of New Jersey Glutamate-enhanced cell-penetrating peptides and methods of using same
CN101812439B (zh) * 2009-02-25 2012-07-04 张舒羽 一种透皮结构域及其衍生的具有透皮作用的融合蛋白和其制备方法
WO2010123971A2 (en) * 2009-04-22 2010-10-28 Board Of Regents, The University Of Texas System Hydrogels for combinatorial delivery of immune-modulating biomolecules
JP2012525146A (ja) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
KR20130139254A (ko) * 2010-11-09 2013-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 피부 침투 및 세포 진입（ｓｐａｃｅ） 펩타이드 및 그의 사용방법
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017082690A1 (ko) * 2015-11-12 2017-05-18 주식회사 펩트론 미백, 피부 탄력, 주름 개선 및 상처치유 활성을 갖는 다기능성 피부투과 펩타이드
WO2021157809A1 (ko) * 2020-02-06 2021-08-12 인천대학교 산학협력단 신규한 핵산 분자 전달용 조성물 및 그 용도

Also Published As

Publication number Publication date
US20170173173A1 (en) 2017-06-22
JP2014500867A (ja) 2014-01-16
US20150025221A1 (en) 2015-01-22
EP2638162A4 (en) 2014-05-28
CA2811113A1 (en) 2012-05-18
US20120128756A1 (en) 2012-05-24
CN103201386A (zh) 2013-07-10
US9441014B2 (en) 2016-09-13
EP2638162B1 (en) 2016-08-10
US8791062B2 (en) 2014-07-29
WO2012064429A2 (en) 2012-05-18
AU2011326732B2 (en) 2016-07-21
WO2012064429A3 (en) 2012-08-02
US8518871B2 (en) 2013-08-27
US20140161871A1 (en) 2014-06-12
AU2011326732A1 (en) 2013-05-02
EP2638162A2 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
US9441014B2 (en) Skin permeating and cell entering (SPACE) peptides and methods of use thereof
CN104640558B (zh) 皮肤透过性肽
Noguchi et al. Effects of lyophilization of arginine-rich cell-penetrating peptide-modified extracellular vesicles on intracellular delivery
JP5721729B2 (ja) 活性産生送達分子
US10611796B2 (en) Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
WO2014123543A2 (en) Skin permeating and cell entering (space) peptides and methods of use therefor
US20140227174A1 (en) Skin permeating and cell entering (space) peptides and methods of use therefor
WO2016033314A1 (en) Skin penetrating peptides (spps) and methods of use therefor
US20250332275A1 (en) Branched Polypeptide Carrier for Efficient Nucleic Acid Delivery and Its Variants
CN119409771A (zh) 一种多肽、多肽/siRNA复合物及其应用
EP4110297B1 (en) Cell-targeted nanoparticles to inhibit rna cargo
JP2025521199A (ja) 有効成分の標的送達のための脂質マイクロバブル
HK1187074A (en) Skin permeating and cell entering (space) peptides and methods of use thereof
HK1234070A1 (en) Skin-permeating peptide
HK1234070B (zh) 皮肤透过性肽

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130402

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid